 "Dr Reddy's hits 52-week high after USFDA issues EIR for Srikakulam facility")
Shares of Dr Reddy’s Laboratories rallied 8 per cent and hit a 52-week high of Rs 4,132 on the National Stock Exchange (NSE) on Friday after the company received the Establishment Inspection Report (EIR) from US health regulator for its manufacturing plant at Srikakulam. The drug maker's stock surpassed its previous high of Rs 4,095, touched on April 22, 2020.
“The company has received the Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA), for the Active Pharmaceutical Ingredients (API) manufacturing plant at Srikakulam, Andhra Pradesh (CTO VI), indicating closure of the audit and the inspection classification of this facility is determined as "Voluntary Action Indicated" (VAI),” Dr Reddy’s Laboratories said in a regulatory filing.
The site was issued warning letter in November, 2015 after the inspection in 2014, and was under "Official Action Indicated" classification till now. With this, all facilities under warning letter are now determined as VAI, it said.
Analysts at Anand Rathi Share and Stock Brokers believe the US business which has been facing revenue pressure, is likely to rebound with new product launches and gradual normalization of price erosion in its key products. Also, Dr Reddy’s should continue to witnesses strong growth in India, emerging markets, Europe and PSAI business driven by volume growth, new launches and improving realizations.
While the deal with Wockhardt strengthens India business, other strategic initiatives of the company focused on building healthy product pipeline, improving efficiency and cost controls, divesting on-core assets and engaging with USFDA to resolve outstanding concerns, create further optimism, the brokerage firm said in value pick.
At 09:42 am, Dr Reddy’s was trading 4 per cent higher at Rs 3,970 on the BSE, as compared to 1.5 per cent rise in the S&P BSE Sensex. A combined around 600,000 equity shares have changed hands on the counter on the NSE and BSE.
“The company has received the Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA), for the Active Pharmaceutical Ingredients (API) manufacturing plant at Srikakulam, Andhra Pradesh (CTO VI), indicating closure of the audit and the inspection classification of this facility is determined as "Voluntary Action Indicated" (VAI),” Dr Reddy’s Laboratories said in a regulatory filing.
The site was issued warning letter in November, 2015 after the inspection in 2014, and was under "Official Action Indicated" classification till now. With this, all facilities under warning letter are now determined as VAI, it said.
Analysts at Anand Rathi Share and Stock Brokers believe the US business which has been facing revenue pressure, is likely to rebound with new product launches and gradual normalization of price erosion in its key products. Also, Dr Reddy’s should continue to witnesses strong growth in India, emerging markets, Europe and PSAI business driven by volume growth, new launches and improving realizations.
While the deal with Wockhardt strengthens India business, other strategic initiatives of the company focused on building healthy product pipeline, improving efficiency and cost controls, divesting on-core assets and engaging with USFDA to resolve outstanding concerns, create further optimism, the brokerage firm said in value pick.
At 09:42 am, Dr Reddy’s was trading 4 per cent higher at Rs 3,970 on the BSE, as compared to 1.5 per cent rise in the S&P BSE Sensex. A combined around 600,000 equity shares have changed hands on the counter on the NSE and BSE.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%